NetraMark offers explainable AI solutions to the Pharma Industry. Delivering insights to optimize trial design, improve success & explain efficacy in subgroups
Joined September 2023
- Tweets36
- Following166
- Followers32
- Likes20
NetraMark.AI retweeted
#ClinicalTrials fail too often and explainable AI may finally fix that.
This episode breaks down how NetraAI @NetraMark_AI uncovers hidden signals in patient data to help good drugs reach the market..
$AIAI.CN $AINMF: A real paradigm shift in precision medicine.
#Biotech
NetraMark.AI retweeted
Just interviewed @NetraMark_AI $AIAI.CN / $AINMF one of the most interesting AI companies in the clinical-trial space.
We covered:
• Why 60–90% of trials fail
• How “personas” can save or rescue Phase 2/3 studies
• Their partnership with Worldwide Clinical Trials
• FDA meeting coming this December
• NIMH collaboration + peer-reviewed publication
This company is doing things most AI companies can’t — explainable, regulator-aligned, real-world AI.
Full interview 👇
🎥 youtu.be/Ae2fSzLXUiE?si=97M_…
Not investment advice. I do not own shares and I was not paid.
NetraMark.AI retweeted
In a new @ZacksSmallCap CEO Chat, @NetraMark_AI $AINMF CEO George Achilleos details how the company’s AI identifies previously unrecognized subpopulations—helping pharma sponsors reduce trial risk and improve outcomes. buff.ly/6fXNxqj
NetraMark.AI retweeted
🧠 Upcoming CfA Webinar | Revolutionizing Depression Care with AI
📅 Friday, July 18, 2025
🕛 12:00 – 1:00 PM ET
Join us for an innovation-driven webinar hosted by our Centre for Analytics, featuring @NetraMark_AI, a Toronto-based startup redefining how we diagnose and treat major depression.
Led by Dr. Goseph Geraci, NetraMark team is using mathematically enhanced AI to uncover hidden subtypes of depression and predict how individuals respond to treatment. Their work is powered by Brain-CODE, OBI’s state-of-the-art neuroinformatics platform. 🔬
Register to join:
braininstitute.ca/news-event…
NetraMark.AI retweeted
Can AI help save billions in failed clinical trials?
Toronto-based @NetraMark_AI (OTCQB: $AINMF) thinks so—and they have the data to back it up.
Their proprietary platform, NetraAI, just outperformed ChatGPT, DeepSeek, and traditional machine learning in uncovering high-impact patient subgroups across trials for schizophrenia, depression, and pancreatic cancer.
prismmarketview.com/can-a-sm…
